• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Bayer AG ADR

Bayer AG ADR

Bayer AG ADR BAYRY 3 Star

Last Price$147.33Day Change (%)0.27%
Open Price$146.32Day Change ($)0.39
Day Range146.32–147.5052-Week Range124.36–147.72

As of Wed 11/26/2014 04:00 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation

    FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation

  2. Research and Markets: Global Hospital Acquired Pneumonia Drugs Pipeline Analysis - 2014 Global Industry Analysis

    Research and Markets: Global Hospital Acquired Pneumonia Drugs Pipeline Analysis - 2014 Global Industry Analysis

  3. Research and Markets: Latin America Home Healthcare Market - Industry Analysis 2014 - 2020

    Research and Markets: Latin America Home Healthcare Market - Industry Analysis 2014 - 2020

  4. Research and Markets: Global Irritable Bowel Syndrome Market 2015-2019: Key Vendors are Actavis, Astellas Pharma, Nestle and Takeda Pharmaceutical

    Research and Markets: Global Irritable Bowel Syndrome Market 2015-2019: Key Vendors are Actavis, Astellas Pharma, Nestle and Takeda Pharmaceutical

  5. ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition

    ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition

  6. Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan

    Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan

  7. Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis

    Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis

  8. Eminent Nanotechnologist Dr. Michael Krueger Joins Quantum Materials Corp

    Eminent Nanotechnologist Dr. Michael Krueger Joins Quantum Materials Corp

  9. Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

    Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

  10. Research and Markets: Global MDI Industry Report 2014-2019

    Research and Markets: Global MDI Industry Report 2014-2019

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.